Home Brand News CIPLA MEDPRO ACQUIRES A STAKE IN CONNECTED HEALTH COMPANY BRANDMED

CIPLA MEDPRO ACQUIRES A STAKE IN CONNECTED HEALTH COMPANY BRANDMED

11
0

In recognition of the importance of the critical shift to a
more patient-centric, integrated and predictive healthcare environment, Cipla
Medpro South Africa (Pty) Limited (“Cipla Medpro”), wholly-owned subsidiary of Cipla
Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as “Cipla”) and South Africa’s
third largest pharmaceutical company in the private sector, will acquire a 30% stake
upon closure in the connected healthcare company, Brandmed (Pty) Limited. In
February, Cipla had announced a similar partnership in India with Wellthy
Therapeutics to offer a clinically-validated digital disease management platform to
patients in cardio-metabolic health.
Brandmed, founded in 2014, has developed a unique fully integrated end to end
solution to address outcomes and value-based care for patients with chronic lifestyle
and Non-Communicable- Diseases (NCDs) such as hypertension, diabetes, high
cholesterol, asthma and chronic obstructive pulmonary disease. KardioGroup, a
subsidiary of Brandmed was awarded the prestigious Frost & Sullivan South African
Product Line Strategy Leadership, Internet of Medical Things South Africa, award in
2019¹.
The Brandmed ecosystem, developed in South Africa, seamlessly integrates a
combination of connected solutions across the health continuum for patients,
healthcare professionals, practices and institutions, and aims to deliver personalised
patient care.
Paul Miller, CEO of Cipla Medpro, said: “This transaction will help to transition
healthcare from being reactive to a proactive and real-time monitoring model that
focuses on promoting wellness instead of managing illness. This aligns with Cipla’s
vision and focus on ‘human care’ and a future where good health is expected, not
for the few, but for the many.”
“By pairing our strengths with Brandmed’ s innovative, patient centric approach to
healthcare, Cipla Medpro will enhance its diverse portfolio in the NCD area to provide
holistic care to patients from awareness through to disease management, thereby
enabling patient adherence and compliance.”
The brainchild behind Brandmed, cardiologist Dr Riaz Motara, said: “Drugs alone are
not enough to manage a disease and the disease burden will become
unmanageable unless innovative solutions are implemented.”
“We’re integrating medical expertise with ground-breaking technology to deliver
better patient care and offer an integrated disease management solution. We’re also
shifting the focus from managing diseases in separate silos to a comprehensive risk
reduction and treatment approach. Greater success in patient health outcomes,
value-based care and efficiencies could be achieved in South Africa if more
healthcare stakeholders are willing to work together,” said Motara.
The Indigo Wellness Index report reveals that South Africa has tremendous scope for
improvement on various health indicators. Measures captured included healthy life
expectancy, blood pressure, blood glucose (diabetes risk), obesity, depression,
happiness, alcohol use, tobacco use, inactivity (too little exercise), and government
spending on healthcare2
.
According to the World Health Organisation, NCDs – mainly cardiovascular diseases,
cancers, chronic respiratory diseases, and diabetes – are the leading cause of death
worldwide. More than 38 million people die annually from NCDs (63% of global
deaths), including 16 million people who die before the age of 70. Nearly 50% of
global disability is attributed to NCDs. Reducing the avoidable burden caused by
NCDs and their risk factors means taking actions now to change the narrative around
NCDs3

LEAVE A REPLY

Please enter your comment!
Please enter your name here